Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Summary

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK inhibitor (BTKi) or BCL-2 inhibitor. The study will evaluate this combination in two parallel cohorts and subjects will be assigned based on which class of novel agent-containing regimen was used prior. Cohort A will consist of patients who progress after BTKi containing regimens and Cohort B will consist of patients who progress after a BCL-2 containing regimen. Subjects who progress on a regimen containing both a BTKi and a BCL-2 inhibitor, will be enrolled in cohort B. Each cohort will be evaluated independently of each other.

Timeline

Start

2021-02-10

Primary completion

2022-01-21

Completion

2022-06-09

Outcome

Outcome not reported

Stopped (Enrollment): “Terminated due to low accrual”

Drugs

Indications